NO332294B1 - Farmasoytisk dronedaron-preparat for parenteral administrering - Google Patents
Farmasoytisk dronedaron-preparat for parenteral administrering Download PDFInfo
- Publication number
- NO332294B1 NO332294B1 NO20031958A NO20031958A NO332294B1 NO 332294 B1 NO332294 B1 NO 332294B1 NO 20031958 A NO20031958 A NO 20031958A NO 20031958 A NO20031958 A NO 20031958A NO 332294 B1 NO332294 B1 NO 332294B1
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical preparation
- cyclodextrin
- dronedarone
- alkali metal
- stated
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 59
- ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229960002084 dronedarone Drugs 0.000 title claims abstract description 24
- 238000007911 parenteral administration Methods 0.000 title claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 239000007853 buffer solution Substances 0.000 claims abstract description 15
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 25
- CPKOXUVSOOKUDA-UHFFFAOYSA-N 1-bromo-5-fluoro-2-iodo-4-methylbenzene Chemical group CC1=CC(I)=C(Br)C=C1F CPKOXUVSOOKUDA-UHFFFAOYSA-N 0.000 claims description 23
- 229960002919 dronedarone hydrochloride Drugs 0.000 claims description 23
- 229910052783 alkali metal Inorganic materials 0.000 claims description 18
- -1 alkali metal acetate Chemical class 0.000 claims description 16
- 229920000858 Cyclodextrin Polymers 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- 229910001463 metal phosphate Inorganic materials 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical class OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000003223 protective agent Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000001384 succinic acid Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 239000008055 phosphate buffer solution Substances 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000010412 perfusion Effects 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 6
- FVIGODVHAVLZOO-UHFFFAOYSA-N Dixanthogen Chemical compound CCOC(=S)SSC(=S)OCC FVIGODVHAVLZOO-UHFFFAOYSA-N 0.000 description 5
- 235000019799 monosodium phosphate Nutrition 0.000 description 4
- 208000001297 phlebitis Diseases 0.000 description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000212749 Zesius chrysomallus Species 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
- DZRJNLPOTUVETG-UHFFFAOYSA-N 1-benzofuran-2-yl(phenyl)methanone Chemical class C=1C2=CC=CC=C2OC=1C(=O)C1=CC=CC=C1 DZRJNLPOTUVETG-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- VGCNHFYRFVWTMU-UHFFFAOYSA-N n-(1-benzofuran-2-yl)methanesulfonamide Chemical class C1=CC=C2OC(NS(=O)(=O)C)=CC2=C1 VGCNHFYRFVWTMU-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0016071A FR2817750B1 (fr) | 2000-12-11 | 2000-12-11 | Composition pharmaceutique de dronedarone pour administration parenterale |
| PCT/FR2001/003903 WO2002047660A1 (fr) | 2000-12-11 | 2001-12-10 | Composition pharmaceutique de dronedarone pour administration parenterale |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20031958D0 NO20031958D0 (no) | 2003-04-29 |
| NO20031958L NO20031958L (no) | 2003-06-11 |
| NO332294B1 true NO332294B1 (no) | 2012-08-20 |
Family
ID=8857483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20031958A NO332294B1 (no) | 2000-12-11 | 2003-04-29 | Farmasoytisk dronedaron-preparat for parenteral administrering |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6939865B2 (ja) |
| EP (1) | EP1343473B1 (ja) |
| JP (1) | JP4399161B2 (ja) |
| KR (1) | KR100849758B1 (ja) |
| CN (1) | CN1235566C (ja) |
| AR (1) | AR031649A1 (ja) |
| AT (1) | ATE348599T1 (ja) |
| AU (2) | AU1722902A (ja) |
| BG (1) | BG66187B1 (ja) |
| BR (1) | BR0116060B1 (ja) |
| CA (1) | CA2427375C (ja) |
| CZ (1) | CZ297788B6 (ja) |
| DE (1) | DE60125411T2 (ja) |
| EA (1) | EA005314B1 (ja) |
| FR (1) | FR2817750B1 (ja) |
| HK (1) | HK1055906A1 (ja) |
| HU (1) | HU229372B1 (ja) |
| IL (2) | IL155428A0 (ja) |
| IS (1) | IS2349B (ja) |
| MA (1) | MA26969A1 (ja) |
| ME (2) | MEP20408A (ja) |
| MX (1) | MXPA03005221A (ja) |
| NO (1) | NO332294B1 (ja) |
| NZ (1) | NZ525661A (ja) |
| OA (1) | OA12416A (ja) |
| PL (1) | PL199846B1 (ja) |
| RS (1) | RS50348B (ja) |
| SK (1) | SK287115B6 (ja) |
| TW (1) | TWI246926B (ja) |
| WO (1) | WO2002047660A1 (ja) |
| ZA (1) | ZA200303406B (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200800177A (en) * | 2006-02-14 | 2008-01-01 | Wyeth Corp | Aqueous pharmaceutical formulations of ERβ selective ligands |
| GB0719180D0 (en) | 2007-10-02 | 2007-11-14 | Cambrex Karlskoga Ab | New process |
| FR2930149B1 (fr) * | 2008-04-17 | 2011-02-18 | Sanofi Aventis | Association de dronedarone avec au moins un diuretique, son application en therapeutique |
| JP2011518785A (ja) * | 2008-04-17 | 2011-06-30 | サノフイ−アベンテイス | 心血管入院または死亡の予防に用いる薬剤を調製するためのドロネダロンの使用 |
| EP2116239A1 (en) * | 2008-04-29 | 2009-11-11 | Sanofi-Aventis | Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment |
| FR2959132A1 (fr) * | 2010-04-22 | 2011-10-28 | Sanofi Aventis | Procedes pour l'evaluation et la reduction des risques |
| TWI508726B (zh) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
| US20120005128A1 (en) * | 2010-06-29 | 2012-01-05 | Sanofi | Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation |
| US8602215B2 (en) | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
| CN102342907A (zh) | 2010-07-30 | 2012-02-08 | 江苏恒瑞医药股份有限公司 | 决奈达隆固体分散体及其制备方法 |
| KR20120094557A (ko) * | 2011-02-01 | 2012-08-27 | 동아제약주식회사 | 피에이치 비의존적 용출양상을 갖는 부정맥치료제 제제 |
| CN102908307A (zh) * | 2011-08-03 | 2013-02-06 | 天津市嵩锐医药科技有限公司 | 供注射用盐酸决奈达隆药物组合物及其制备方法 |
| AR091727A1 (es) * | 2012-07-12 | 2015-02-25 | Sanofi Sa | Composicion anti-tumoral que comprende el compuesto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)urea |
| TW202227049A (zh) * | 2020-10-20 | 2022-07-16 | 大陸商上海博志研新藥物技術有限公司 | 鹽酸決奈達隆藥物組合物、其製備方法及應用 |
| WO2023019993A1 (zh) * | 2021-08-16 | 2023-02-23 | 上海博志研新药物技术有限公司 | 盐酸决奈达隆注射组合物、其制备方法及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| FR2746013B1 (fr) * | 1996-03-18 | 1998-05-29 | Sanofi Sa | Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus |
| JP2004327321A (ja) * | 2003-04-25 | 2004-11-18 | Jst Mfg Co Ltd | コネクタ |
-
2000
- 2000-12-11 FR FR0016071A patent/FR2817750B1/fr not_active Expired - Fee Related
-
2001
- 2001-12-10 BR BRPI0116060-5B1A patent/BR0116060B1/pt not_active IP Right Cessation
- 2001-12-10 TW TW090130522A patent/TWI246926B/zh not_active IP Right Cessation
- 2001-12-10 AR ARP010105716A patent/AR031649A1/es not_active Application Discontinuation
- 2001-12-10 WO PCT/FR2001/003903 patent/WO2002047660A1/fr active IP Right Grant
- 2001-12-10 AU AU1722902A patent/AU1722902A/xx active Pending
- 2001-12-10 EA EA200300406A patent/EA005314B1/ru not_active IP Right Cessation
- 2001-12-10 ME MEP-204/08A patent/MEP20408A/xx unknown
- 2001-12-10 RS YUP-465/03A patent/RS50348B/sr unknown
- 2001-12-10 MX MXPA03005221A patent/MXPA03005221A/es active IP Right Grant
- 2001-12-10 IL IL15542801A patent/IL155428A0/xx active IP Right Grant
- 2001-12-10 AT AT01270322T patent/ATE348599T1/de not_active IP Right Cessation
- 2001-12-10 NZ NZ525661A patent/NZ525661A/en not_active IP Right Cessation
- 2001-12-10 OA OA1200300152A patent/OA12416A/fr unknown
- 2001-12-10 SK SK726-2003A patent/SK287115B6/sk not_active IP Right Cessation
- 2001-12-10 CA CA2427375A patent/CA2427375C/fr not_active Expired - Fee Related
- 2001-12-10 KR KR1020037007744A patent/KR100849758B1/ko active IP Right Grant
- 2001-12-10 JP JP2002549234A patent/JP4399161B2/ja not_active Expired - Fee Related
- 2001-12-10 HU HU0500842A patent/HU229372B1/hu not_active IP Right Cessation
- 2001-12-10 ZA ZA200303406A patent/ZA200303406B/en unknown
- 2001-12-10 CZ CZ20031612A patent/CZ297788B6/cs not_active IP Right Cessation
- 2001-12-10 EP EP01270322A patent/EP1343473B1/fr not_active Expired - Lifetime
- 2001-12-10 PL PL362788A patent/PL199846B1/pl unknown
- 2001-12-10 CN CNB018203884A patent/CN1235566C/zh not_active Expired - Fee Related
- 2001-12-10 US US10/450,320 patent/US6939865B2/en not_active Expired - Lifetime
- 2001-12-10 ME MEP-2008-204A patent/ME00083B/me unknown
- 2001-12-10 AU AU2002217229A patent/AU2002217229B2/en not_active Ceased
- 2001-12-10 DE DE60125411T patent/DE60125411T2/de not_active Expired - Lifetime
-
2003
- 2003-04-14 IL IL155428A patent/IL155428A/en not_active IP Right Cessation
- 2003-04-18 BG BG107748A patent/BG66187B1/bg unknown
- 2003-04-29 NO NO20031958A patent/NO332294B1/no not_active IP Right Cessation
- 2003-04-30 IS IS6801A patent/IS2349B/is unknown
- 2003-06-03 MA MA27190A patent/MA26969A1/fr unknown
- 2003-11-14 HK HK03108327A patent/HK1055906A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO332294B1 (no) | Farmasoytisk dronedaron-preparat for parenteral administrering | |
| CA2483774C (en) | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin | |
| JP3137987B2 (ja) | 非経口デリバリー用アミオダロン医薬組成物 | |
| JP4708648B2 (ja) | レボシメンダンの医薬溶液 | |
| KR100195348B1 (ko) | 안정한 프로스타글란딘 e1-함유 주사제 조성물 | |
| US20100267817A1 (en) | Lyophilized pharmaceutical composition with improved reconstitution time containing taxane derivatives and method of manufacturing the same | |
| JP4316834B2 (ja) | アミオダロン含有非経口溶液 | |
| JPH115744A (ja) | ヒアルロン酸含有の外用水溶液製剤 | |
| JP3720262B2 (ja) | 安定化したカルベジロール注射溶液 | |
| JP4278115B2 (ja) | キヌプリスチン及びダルホプリスチンに基づく安定化された製薬学的組成物並びにそれらの製造 | |
| KR920004098B1 (ko) | 레베카마이신 동족체의 안정 용액 및 그의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |